Ownership
Private
Employees
~48
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Precision fermentationengineered yeast-based production

Evolva General Information

Evolva has commercialized several nature-based ingredients produced via precision fermentation; notable products include Veri-te resveratrol and aroma components like Valencene and Nootkatone. The company was acquired by Lallemand in late 2023 to expand its global reach.

Contact Information

Website
Primary Industry
Non-Drug Biotech
Corporate Office
Reinach, Basilea-Country/Basel-Landschaft
Switzerland

Drug Pipeline

Veri-te resveratrol
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Evolva's pipeline data

Book a demo

Key Partnerships

Now part of the broader partnership network of Lallemand Inc.; previous partnerships not detailed in current results.

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Evolva Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Evolva's complete valuation and funding history, request access »

Evolva Financial Metrics